The FDA approved delafloxacin, which exhibits activity against both gram-positive and gram-negative pathogens, including methicillin-resistant S aureus, in 2017 for the treatment of ABSSSI. It is available in both intravenous and oral formulations. Daptomycin and vancomycin can treat ABSSSI, but neither is effective against gram-negative pathogens. Nafcillin is effective against gram-positive pathogens only and is not indicated for the treatment of ABSSSI.
Learn more about delafloxacin.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Fast Five Quiz: Cellulitis - Medscape - May 22, 2023.
Comments